Vein access device effective in early study:
This article was originally published in Clinica
Executive Summary
An implantable device which provides access to the veins of haemodialysis patients has worked well in a preliminary study of patients at the Austin Diagnostic Center in Texas. The LifeSite device, a stainless steel and titanium alloy valve implanted just under the skin, was developed by Topsfield, Massachusetts-based VascA. According to the results of the study, it allowed increased blood flow and was free from thrombosis in all ten patients. The device, which is already sold in Canada and Europe, is designed as an alternative to fistulas, synthetic grafts and dialysis catheters.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.